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INTRODUCTION
Thrombotic microangiopathy (TMA) encompasses severe con-
ditions caused by microvascular thrombosis including thrombotic 
thrombocytopenic purpura (TTP) and Shiga toxin-mediated hemo-
lytic uremic syndrome (HUS).1 These disorders, associated with 
high morbidity, share unifying features: microangiopathic hemo-
lytic anemia (MAHA), thrombocytopenia, and organ disfunction.2 
MAHA describes Coombs-negative hemolysis from intravascular 
red blood cell fragmentation producing schistocytes on peripheral 
blood smear.3 TTP and HUS are not the only forms of TMA. Cases 
of metabolism mediated TMA from vitamin B12 deficiency have 
been reported termed pseudothrombotic microangiopathy (pseudo-
TMA).4-6 Differentiating the etiology of TMA, specifically TTP and 
vitamin B12 deficiency is critical as the treatments and prognoses are 
different. Treatment for TTP requires plasma exchange associated 
with increased complications and cost as compared to the treatment 
for vitamin B12 deficiency, which is simply supplementation.7 Unnec-
essary plasma exchange has been reported due to the misdiagnosis of 
TTP when the actual diagnosis was vitamin B12 deficiency.8 
The incidence of TTP is less than one case per year per million.9 
Vitamin B12 deficiency, on the other hand, is far more common. The 
most frequent serum vitamin B12 cut-off level to diagnose vitamin 
B12 deficiency is 150 pmol/L (203 pg/ml). Using this serum vitamin 
B12 cut-off level, the prevalence of vitamin B12 deficiency is 5% to 
15%.10 Approximately 2.5% of vitamin B12 deficiency cases present 
with hemolytic anemia, thrombocytopenia, and schistocytosis.11 
Therefore, even though a small proportion of vitamin B12 presents 
with MAHA, the incidence is higher than TTP. We report a case of 
a man presenting with profound pancytopenia concerning for TTP 
that was actually secondary to vitamin B12 deficiency.
CASE REPORT
A 65-year-old Caucasian male with a history of hepatitis C pre-
sented to the emergency room after laboratory evaluation at his 
primary care provider’s office revealed pancytopenia. He endorsed a 
one-month history of increasing fatigue, interfering with his work as 
a security guard. He denied a history of blood or coagulation disor-
ders, autoimmune disease, cancer, recent trauma, immobilization, or 
travel. He initially denied any history of heavy alcohol consumption.
Vital signs were within normal limits. On physical exam, con-
junctival pallor was noted. Cardiovascular exam was significant for
 a 2/6 systolic murmur. He had bilateral 1+ pitting edema of the lower 
extremities to the mid-calf with discoloration consistent with venous 
stasis. His skin showed diffuse ecchymosis of the forearms bilaterally. 
Table 1 shows lab values on admission.
A peripheral blood smear showed 4% schistocytes, 2+ teardrop 
cells, and hypersegmented neutrophils. Coomb’s test was negative. 
His iron studies and folate levels were within normal limits. Coagu-
lation studies were within normal limits. The patient was transfused 
with packed red blood cells. A diagnosis of vitamin B12 deficiency was 
made and treatment with intramuscular vitamin B12 initiated. After 
further questioning, he disclosed that his diet consisted almost exclu-
sively of tomato soup and meatless sandwiches. Since the death of his 
father and brother earlier in the year, he had increased his alcohol 
consumption significantly more than he initially indicated, drinking 
around 8 - 10 beers daily. His ADAMTS13 activity later returned as 
100% activity.  He was treated with intramuscular vitamin B12 and 
follow-up as an outpatient showed complete resolution of his anemia 
four months later.
Table 1. Lab values on admission. 
Lab Value Reference Range
WBC 1.6 K/cmm 3.60 - 11.20
Hemoglobin 4.8 g/dl 13.1 - 16.8
Hematocrit 15.0% 38.2 - 48.4
Platelet count 34 K/cm 150 - 400
Mean corpuscular volume 121.3 fL 80.1 - 98.5
Reticulocyte count 3.8% 0.50 - 2.3
Reticulocyte count, ABS 0.046 M/ul 0.022 - 0.101
Total bilirubin 1.6 mg/dL 0.2 - 1.2
Direct bilirubin 0.7 U/L 0.0 - 0.5
Lactate dehydrogenase 3449 Units/L 125 - 243
Creatinine 0.76 mg/dL 0.7 - 1.3
Haptoglobin < 8 mg/dL 44 - 215
Vitamin B12 66 pg/mL 213 - 816
Parietal cell antibody 62.5 Unit ≤ 20.0
Intrinsic factor Ab Negative Negative
DISCUSSION
Patients showing schistocytosis and thrombocytopenia merit 
screening for TTP as this disease can be lethal. The PLASMIC 
score (Table 2) quantifies the likelihood of TTP.12 Each criterion 
scores a point. If the score is in the intermediate to high range (5 to 7 
points), a presumptive diagnosis in the appropriate clinical context 
can be made and is sufficient to initiate treatment. Our patient’s 
PLASMIC score of 5 fell into the intermediate risk. However, his 
clinical presentation was due solely to vitamin B12 deficiency. Dif-
ferentiating vitamin B12 deficiency with pseudo-TMA from TTP is 
of the utmost importance to avoid unnecessary plasma exchange. 
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As with TTP, vitamin B12 deficiency also can present with MAHA and 
thrombocytopenia, as seen in our case.
Table 2. PLASMIC score template. 
PLASMIC Indications (1 point for each indication)
Platelet count < 30,000/microL
One or more indicators of hemolysis: Reticulocyte count (percentage > 
2.5% or haptoglobin undetectable or indirect bilirubin > 2.0 mg/dL
No active cancer in the preceding year
No history of solid organ or hematopoietic stem cell transplant
Mean corpuscular volume (MCV) < 90 femtoliters
International normalized ratio (INR) < 1.5
Creatinine < 2.0 mg/dL
PLASMIC score:  Risk of severe ADAMTS13 deficiency 
0 to 4: Low risk
5:  Intermediate risk
6 to 7:  High risk
 
      Vitamin B12 is necessary for the proper synthesis of deoxyribo-
nucleic acid (DNA) and cell division of hematopoietic cells.13 Without 
adequate stores the nucleated precursors of hematopoietic cells, lines 
cannot mature, leading to megaloblastic anemia. Neutropenia and 
thrombocytopenia subsequently may develop.14 As the precursor cells 
are unable to mature, cellular arrest occurs, leading to intramedul-
lary cell death. Lactate dehydrogenase (LDH) enzymes are released 
during the destruction of nucleated red cells. Therefore, intramedul-
lary hemolysis of immature red blood cells, as seen in vitamin B12 
deficiency, can lead to high LDH levels. In fact, LDH levels may be 
useful in differentiating TTP from vitamin B12 deficiency, as most 
patients with TTP exhibit LDH levels less than 2500 IU/L, while 
levels exceeding 2500 IU/L indicate the possibility of vitamin B12 
deficiency.15
As bilirubin elevation results from the catabolism of heme, the 
hemolysis of erythroid precursors, which produce little hemoglo-
bin, results in only a minor increase in bilirubin levels.16 In contrast, 
peripheral hemolysis of mature erythrocytes, which have a high 
amount of hemoglobin, leads to a much higher indirect bilirubin level. 
Our patient’s LDH levels were much higher relative to his bilirubin 
levels, more consistent with intramedullary hemolysis of immature 
erythrocytes secondary to vitamin B12 deficiency. 
ADAMTS13 cleaves von Willebrand factor multimers that are 
secreted from vascular endothelial cells.17 ADAMTS13 deficiency 
results in unusually large von Willebrand factor multimers, causing 
platelet thrombi in small vessels with high shear rates, creating schis-
tocytes. Vitamin B12 causes hyperhomocysteinemia, decreased 
plasma methionine levels, and methylmalonic aciduria. These are 
associated with platelet activation, generation of reactive oxygen 
species, endothelial dysfunction, increased tissue factor expres-
sion, and coagulation activation. The combination of these factors is 
thought to lead to peripheral hemolysis, causing schistocytes. Indi-
viduals with homozygous or compound heterozygous mutations in a 
gene encoding the methylmalonic aciduria and homocystinuria type C 
protein (MMACHC) are more predisposed to pseudo-TMA as com-
pared to vitamin B12 deficiency without MAHA.
The most helpful parameter in differentiating pseudo-TMA and 
TTP may be the reticulocyte count.15 Those who have pseudo-TMA 
averaged a 3% reticulocyte count and TTP averaged 18%.18 Our 
patient’s level of 3.8% was more consistent with vitamin B12 defi-
ciency. The reticulocyte production index (RPI) makes corrections 
for both the hematocrit and the reticulocyte lifespan.19 Making these 
corrections determines whether the reticulocytosis truly is increased. 
In cases of anemia, RPI less than 2 is considered inappropriately low. 
Our patient’s RI was 0.50, indicating a hypoproliferative process.
Both TMA and vitamin B12 deficiency can present with a high 
MCV.20 In the setting of hemolytic disorders, a high MCV can be due 
to a high reticulocyte count. Severe macrocytosis with levels greater 
than 115 fL is associated almost exclusively with megaloblastic 
anemias, including vitamin B12 deficiency. Our patient’s high MCV 
with a low RI is more consistent with megaloblastic anemia rather 
than TTP. Of note, ADAMTS13 activity level typically is decreased in 
TTP; however, due to time limitations, treatment decisions often are 
initiated prior to obtaining it.
CONCLUSION
In summary, vitamin B12 deficiency associated with pseudo-TMA 
can present similarly to TTP with hemolytic anemia, schistocytosis, 
and thrombocytopenia. Obtaining the correct diagnosis is possible if 
the clinician understands the clinical differences and differing mech-
anisms. Vitamin B12 deficiency typically presents with an elevated 
MCV and relatively low reticulocyte count, whereas TTP may or may 
not present with an elevated MCV and elevated reticulocyte count.18,20 
MCV greater than 115 fL is consistent with megaloblastic anemias. 
Vitamin B12 deficiency typically presents with relatively higher levels 
of LDH and lower levels of bilirubin compared with TMA.15,16 MAHA 
is a feature of both TMA and pseudo-TTP, however, the etiologies of 
the two differ.17 
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